Phenescaline

Last updated

Phenescaline
Phenescaline.svg
Clinical data
Other names3,5-Dimethoxy-4-phenylethoxyphenethylamine; 4-Phenylethoxy-3,5-dimethoxyphenethylamine
Routes of
administration 		Oral [1]
Drug class Serotonin receptor modulator; Serotonin 5-HT2A receptor antagonist
ATC code
  • None
Pharmacokinetic data
Duration of action Unknown [1]
Identifiers
  • 2-[3,5-dimethoxy-4-(2-phenylethoxy)phenyl]ethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C18H32NO3
Molar mass 310.458 g·mol−1
3D model (JSmol)
  • COc2cc(cc(OC)c2OCCc1ccccc1)CCN
  • InChI=1S/C18H23NO3/c1-20-16-12-15(8-10-19)13-17(21-2)18(16)22-11-9-14-6-4-3-5-7-14/h3-7,12-13H,8-11,19H2,1-2H3 Yes check.svgY
  • Key:FKXBCTFKCKEDNI-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Phenescaline, or 3,5-dimethoxy-4-phenylethoxyphenethylamine, is a lesser-known drug of the phenethylamine and scaline families [1] It is an analogue of mescaline. Alexander Shulgin first synthesized phenescaline. [1] In his book PiHKAL (Phenethylamines i Have Known And Loved) , the minimum dose is listed as 150 mg, and the duration is unknown. [1] Phenescaline produces a threshold effect. [1] Very little data exists about the pharmacological properties, metabolism, and toxicity of phenescaline. [1] The drug is an antagonist of the serotonin 5-HT2A receptor, with an affinity (Ki) of 59 nM. [2] [ additional citation(s) needed ]

Contents

See also

References

  1. 1 2 3 4 5 6 7 Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628.
  2. ↑ Parker MA, Kurrasch DM, Nichols DE (April 2008). "The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands". Bioorganic & Medicinal Chemistry. 16 (8): 4661–4669. doi:10.1016/j.bmc.2008.02.033. PMC   2442558 . PMID   18296055. Compound 21, code PE
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.